002720 — Kukje Pharma Co Balance Sheet
0.000.00%
- KR₩104bn
- KR₩124bn
- KR₩175bn
Annual balance sheet for Kukje Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 7,903 | 5,559 | 10,632 | 8,755 | 10,724 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 23,486 | 20,359 | 22,141 | 24,656 | 29,845 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 48,197 | 48,535 | 55,119 | 56,974 | 67,377 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 81,981 | 78,380 | 99,124 | 98,185 | 98,443 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 139,783 | 136,593 | 163,259 | 165,548 | 182,276 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 54,517 | 47,855 | 59,687 | 28,547 | 62,020 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 71,215 | 62,519 | 78,315 | 76,006 | 84,588 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 68,568 | 74,074 | 84,944 | 89,542 | 97,689 |
| Total Liabilities & Shareholders' Equity | 139,783 | 136,593 | 163,259 | 165,548 | 182,276 |
| Total Common Shares Outstanding |